Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study

Ying Yao1,2, Ping Wang1,2, Xiao-Zeng Wang1, Xin Zhao1, Wei Zhao1, Tie-Nan Zhou1, Lei Zhang1

1Department of Cardiology, Institute of Cardiovascular Research, General Hospital of Northern Theater Command, Shenyang, Liaoning 110840, China; 2Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China.

Abstract

Background: The dose and time point for switching from clopidogrel to ticagrelor remain controversial, especially for Chinese acute coronary artery disease (ACS) patients with complicated coronary artery disease (CAD). Hence, the purpose of this study was to further explore the optimal dose and time point for the switching strategy to balance the increase in platelet inhibition and the decrease in adverse events in Chinese ACS patients with complicated CAD managed by percutaneous coronary intervention (PCI).

Methods: From July 2017 to December 2017, the prospective, randomized, open-label study (the Switching from clopidogrel to ticagrelor study) assigned the eligible Chinese ACS patients with complicated CAD managed by PCI (n = 102) for 90 mg of ticagrelor at 12 h (T-90 mg-12 h), 90 mg of ticagrelor at 24 h (T-90 mg-24 h) or 180 mg ticagrelor at 24 h (T-180 mg-24 h) after the last dose of clopidogrel. The primary endpoint was the comparison of maximal platelet aggregation (MPA) values at 2 h after switching strategies among the three groups. In addition, the MPA values at baseline, 8 h and before discharge and the rates of high on-treatment platelet reactivity were evaluated, the incidences of bleeding episodes and dyspnea during hospitalization and at 30-day follow-up in our study were also recorded. The MPA was measured by light transmittance aggregometry in our study. A repeated-measures analysis of variance (ANOVA) model and one-way ANOVA were used to compare data for the primary endpoint.

Results: The MPA values were significantly decreased in the T-180 mg-24 h group compared with the T-90 mg-12 h group (P = 0.017) and decreased numerically compared with the T-90 mg-24 h group (P = 0.072) at 2 h. In particular, the MPA values were markedly reduced in the T-90 mg-24 h group compared with the T-90 mg-12 h group at 8 h after switching treatment (P = 0.002). There was no significant difference among the three groups in all bleedings and dyspnea events.

Conclusions: The optimal treatment strategy recommended in this study for Chinese ACS patients with complicated CAD managed by PCI is 180 or 90 mg of ticagrelor at 24 h after the last dose of clopidogrel. In addition, a negative interaction was detected in this study between the overlap for clopidogrel and ticagrelor at 12 h after the last dose of clopidogrel.

Trial Registration: ClinicalTrials.gov, NCT03577652; http://clinicaltrials.gov/ct2/show/NCT03577652.

Keywords: Clopidogrel; Drug substitution; Pharmacology; Ticagrelor

Introduction

Dual anti-platelet therapy is the cornerstone in the management of acute coronary syndrome (ACS), including complicated coronary artery disease (CAD) managed by percutaneous coronary intervention (PCI).1,2 Complicated CAD is strongly associated with poor prognosis, requiring more potent inhibition of platelet aggregation.1,3-5 As a member of the new chemical class cyclo-pentyl-triazolo-pyrimidines of the P2Y12 blockers, ticagrelor provides faster, greater, and more consistent P2Y12 inhibition than clopidogrel.6,7 Compared with clopidogrel, ticagrelor is related to a lower risk of ischemic events, as shown in the PLATElet inhibition and patient outcomes (PLATO) randomized trial, especially in the patients with complicated CAD.8-10 However, ticagrelor is also associated with an increased incidence of bleeding complications not related to coronary artery bypass surgery compared with clopidogrel, and dyspnea is more common among patients receiving ticagrelor.11-13 Additionally, confirmation of the diagnosis of complicated CAD often requires coronary angiography. As noted previously, more patients were treated with clopidogrel than ticagrelor before coronary angiography in clinical...
practice. This treatment scheme may lead to the switch from clopidogrel to ticagrelor in patients becoming common in the real world. The latest guidelines referenced the only trial on switching between clopidogrel and ticagrelor, which was conducted for powering of clinical endpoints, hence that study was not specifically contributing to a switching strategy including the best timing, dosage, and specific population.\(^1,\)\(^8\) Hence, the purpose of this study was to further explore the optimal dose and time point for the switching strategy to balance the increase in platelet inhibition and the decrease in adverse events in Chinese ACS patients with complicated CAD managed by PCI.

**Methods**

**Ethical approval**

This study was approved by local ethics committee of the General Hospital of Northern Theater Command and informed consent was obtained from every candidate at the beginning of the study. The trial was carried out in accordance with the principles of the *Declaration of Helsinki.*\(^1,\)\(^14\)

**Study design**

The SwitcHIng from clopidogrel to ticagrelor study (Clinicaltrials.gov, NCT03577652) was a prospective, randomized, open-label, single-center study. From July 2017 to December 2017, we enrolled Chinese ACS patients with complicated CAD who had been treated with a maintenance dose or loading dose of clopidogrel before coronary angiography and underwent successful drug-eluting stent implantation [specific study inclusion criteria are shown in the Supplementary materials Table S1, http://links.lww.com/CM9/A94]. Combining the clinical actual circumstances in China with the Synergy Between PCI With Taxus and Cardiac Surgery score, complicated CAD was defined as follows in this trial: (1) left main disease; (2) lesion length $>20\, \text{mm}$; (3) tortuous lesions ($\geq 3$ coronary artery branches and bent $\geq 45^\circ$ along at least one arterial trunk); (4) small vascular lesions (blood vessel diameter $\leq 2.75\, \text{mm}$); (5) bifurcation lesions; (6) heavy calcification; and (7) in-stent restenosis.\(^1,\)\(^5\) We excluded patients for whom ticagrelor treatment was contraindicated or those at a high-risk for bleeding [specific study exclusion criteria are shown in the Supplementary materials Table S1, http://links.lww.com/CM9/A94].

**Randomization and treatment**

After PCI, the eligible patients were randomly allocated into three groups: group A, which received 90 mg of ticagrelor plus 100 mg of aspirin at 12 h after the last dose of clopidogrel (T-90 mg-12 h); group B, which received 90 mg of ticagrelor plus 100 mg of aspirin at 24 h after the last dose of clopidogrel (T-90 mg-24 h); and group C, which received 180 mg of ticagrelor plus 100 mg of aspirin at 24 h after the last dose of clopidogrel (T-180 mg-24 h). All patients were then given 90 mg of ticagrelor twice daily plus 100 mg of aspirin once daily at the beginning of the next administration and the treatment maintained for at least 30 days after discharge. Other cardiac medications were given at the direction of physicians. The randomization sequence was generated by using random number table. A flow diagram of the study is presented in Figure 1A.

**Platelet function assessments**

Venous blood samples were collected from every patient at the following time points: baseline (before accepting the first ticagrelor dose; for example, the venous blood samples in the T-90 mg-12 h group were collected at 12 h after the last clopidogrel treatment but before the first ticagrelor treatment), 2 h after conversion (2 h after the first administration of the scheduled ticagrelor treatment), 8 h after conversion (8 h after the first administration of the scheduled ticagrelor treatment), and before discharge (2 h after conversion). The platelet function assessment was measured by light transmittance aggregometry. Baseline values were measured while on clopidogrel maintenance therapy. Before discharge values were measured at 2 h after the last dose of ticagrelor during hospital.**

**Figure 1:** Study design and patient disposition. (A) Adverse events include bleeding episodes and dyspnea. The MPA was measured by light transmittance aggregometry. Baseline values were measured while on clopidogrel maintenance therapy. Before discharge values were measured at 2 h after the last dose of ticagrelor during hospital. (B) Patient disposition. In total, 102 patients of the intention-to-treat analysis population formed the efficacy and safety endpoint cohorts. T-90 mg-12 h: Maintenance dose of 90 mg of ticagrelor at 12 h after the last clopidogrel treatment; T-90 mg-24 h: Maintenance dose of 90 mg of ticagrelor at 24 h after the last clopidogrel treatment; T-180 mg-24 h: Loading dose of 180 mg of ticagrelor at 24 h after the last clopidogrel treatment; ACS: Acute coronary syndrome; MPA: Maximal platelet aggregation; PCI: Percutaneous coronary intervention; R: Randomization.
after the last dose of ticagrelor during hospitalization). Samples were measured by light transmittance aggregometry (LTA) following the application of 20 μmol/L adenosine diphosphate (ADP). Maximal platelet aggregation (MPA) was determined to represent the extent of platelet aggregation and expressed as the maximum percent change in light transmittance.\(^{16-18}\) In accordance with previous studies, high on-treatment platelet reactivity (HPR) was defined as MPA > 59% (LTA, 20 μmol/L ADP) in the present study.\(^{19,20}\)

**Outcomes and follow-up**

The primary endpoint was the comparison of MPA values at 2 h after switching strategies among the three groups. The secondary endpoints included comparisons of MPA values at the remaining time points among all three groups and the rates of HPR in all three groups at each pre-set time point. Adverse events comprised of bleeding events (defined according to the Bleeding Academic Research consortium [BARC] criteria, thrombolysis in myocardial infarction [TIMI] criteria and PLATO bleeding criteria) and dyspnea at 30 days after discharge and during hospitalization were also evaluated.\(^{8,21-23}\) All participants were contacted by a phone call to assess study endpoints. The clinical incidents were gathered by the treating clinicians and were analyzed by investigators.

**Statistical analysis**

The intention-to-treat analysis was used to analyze the results in our study. Based on preliminary experiment in this study and the previous research, we estimated that the mean MPA of treating with 180 mg ticagrelor would be 17% at 2 h after switching treatment and a loading does of ticagrelor therapy would result in a decrease in MPA of 40% compared with 90 mg ticagrelor therapy.\(^{24,25}\) A sample size of 32 patients per group would be required with a 80% power and an α of 0.05. Therefore, considering a dropout rate of approximately 10%, 36 patients in each group were needed to ensure complete data. The mean ± standard deviation (SD) was presented for the continuous variables, and categorical variables were expressed as counts and percentages. The Kolmogorov-Smirnov test was performed to estimate whether a normal distribution was observed among continuous variables. If normality assumptions were not satisfied, the Kruskal-Wallis test was used, and data were expressed as medians. Categorical variables were compared by the χ² test or Fisher exact test between groups, and we used one-way analysis of variance (ANOVA) to analyze continuous variables. A repeated-measures ANOVA model and one-way ANOVA were used to compare data at the primary endpoint and at each pre-set time point among all three groups as well as evaluating the difference between groups over time points. A linear regression model was used to assess the association between the MPA levels and the time interval or dosage. A two-tailed value of \(P < 0.05\) was used to demonstrate a statistically significant difference for all the statistical analyses. Statistical analyses were performed with SPSS version 24.0 software (IBM Corporation, Armonk, NY, USA).

**Results**

**Baseline characteristics**

A total of 102 Chinese patients were included in the intention-to-treatment analysis and formed the efficacy and safety populations. Four patients pre-maturely dropped out from the study because of severe side effects and non-compliance, hence, a total of 98 patients completed the entire follow-up [Figure 1B]. Table 1 summarizes the baseline characteristics of the study cohort, which were balanced among all the treatment groups. The angiographic and procedural characteristics are described in the Supplementary materials Table S1, http://links.lww.com/CM9/A94.

**Pharmacodynamic findings**

In general, MPA levels were lower over the study time course with T-180 mg-24 h group vs. T-90 mg-12 h group \((P = 0.010)\), but similar to T-90 mg-24 h group \((P = 0.184)\). There were differences numerically in MPA levels over time between T-90 mg-12 h group and T-90 mg-24 h group \((P = 0.191)\).

Platelet function as expressed by MPA was measured by LTA and illustrated in Figure 2 and the Supplementary materials Table S3, http://links.lww.com/CM9/A94. The baseline levels of MPA were balanced among the groups \((P = 0.941)\). The MPA values in all three conversion strategies were significantly reduced after the switch from clopidogrel to ticagrelor compared with baseline levels in our study [Supplementary materials Figure S1, http://links.lww.com/CM9/A94]. At 2 h after switching from clopidogrel to ticagrelor, the MPA values were lower in the T-180 mg-24 h group than in the T-90 mg-12 h group \((28.22\% \text{ vs. } 17.23\%, P = 0.017)\), and there was a non-significant decrease in MPA values between the T-180 mg-24 h group and T-90 mg-24 h group \((25.44\% \text{ vs. } 17.23\%, P = 0.072)\). The difference in platelet aggregation in the T-180 mg-24 h group compared with the other groups persisted at the 8 h time point \((28.46\% \text{ vs. } 12.19\%, P_{\text{T-180}} = 0.001; 18.20\% \text{ vs. } 12.19\%, P_{\text{T-90mg-24 h vs. T-90mg-12 h}} = 0.073)\). The rates of HPR were not markedly different at each time point among three groups [Table 2].

Then we analyzed platelet reactivity between the T-90 mg-24 h and the T-90 mg-12 h group to investigate whether exposure to clopidogrel could interfere with ticagrelor-induced anti-platelet effects. Notably, there was a significant difference in MPA values between the T-90 mg-24 h and the T-90 mg-12 h groups at 8 h after switching the treatment \((28.46\% \text{ vs. } 18.20\%, P = 0.002)\). The repeated measures ANOVA analysis confirmed that the study treatment (group A vs. group B vs. group C) and the pre-set time points (baseline, 2 and 8 h, before discharge) indeed had an effect on platelet aggregation \((F = 151.621, P_{\text{pre-set time points}} = 0.001; F = 3.448, P_{\text{study treatment}} = 0.036)\). Furthermore, there was an interaction effect between the pre-set time points and the study treatment \((F = 5.276, P_{\text{interaction}} = 0.002)\), and the significant difference in MPA values between the T-90 mg-24 h and the T-90 mg-12 h groups at 8 h was validated by simple effect analysis \((t = 10.257, P = 0.006)\). The baseline variables,
Table 1: Baseline characteristics of the Chinese patients with acute coronary syndrome patients with complicated coronary artery.

| Variables                      | T-90 mg-12 h (n = 35) | T-90 mg-24 h (n = 35) | T-180 mg-24 h (n = 32) | Statistics | P     |
|--------------------------------|-----------------------|-----------------------|------------------------|------------|-------|
| Age (years)                    | 57.06 ± 10.53         | 59.46 ± 9.15          | 60.97 ± 8.11           | 1.500†     | 0.228 |
| Male                           | 29 (82.9)             | 29 (82.9)             | 22 (68.8)              | 2.584†     | 0.275 |
| BMI (kg/m²)                    | 27.16 ± 3.39          | 26.66 ± 3.06          | 26.30 ± 3.79           | 0.367‡     | 0.582 |
| Smoking                        | 19 (54.3)             | 21 (60.0)             | 13 (40.6)              | 2.629‡     | 0.269 |
| Diabetes mellitus              | 14 (40.0)             | 12 (34.3)             | 11 (34.4)              | 0.320‡     | 0.852 |
| Hypertension                   | 21 (60.0)             | 18 (51.4)             | 19 (59.4)              | 0.644‡     | 0.725 |
| Dyslipidemia                   | 29 (82.9)             | 25 (71.4)             | 19 (63.3)              | 6.155‡     | 0.119 |
| Prior MI                       | 5 (14.3)              | 10 (28.6)             | 3 (9.4)                | 4.633†     | 0.098 |
| Prior stroke                   | 5 (14.3)              | 4 (11.4)              | 2 (6.3)                | 1.157‡     | 0.619 |
| Prior PAD                      | 3 (8.6)               | 0                     | 0                      | 4.019†     | 0.105 |
| Prior PCI                      | 8 (22.9)              | 10 (28.6)             | 3 (9.4)                | 3.936‡     | 0.140 |
| Presentation                   |                      |                       |                        | 2.191†     | 0.345 |
| STEMI                          | 1 (2.9)               | 3 (8.6)               | 4 (12.5)               |            |       |
| UA or NSTEMI                   | 34 (97.1)             | 32 (91.4)             | 28 (87.5)              |            |       |
| Medications                    |                       |                       |                        |            |       |
| Beta-blocker                   | 29 (82.9)             | 26 (74.3)             | 26 (81.3)              | 0.883‡     | 0.643 |
| CCB                            | 17 (48.6)             | 14 (40.0)             | 10 (31.3)              | 2.087‡     | 0.352 |
| Statins                        | 35 (100.0)            | 35 (100.0)            | 32 (100.0)             | −          | 1.000 |
| ACEI or ARB                    | 23 (65.7)             | 25 (71.4)             | 29 (90.6)              | 6.081‡     | 0.048 |
| PPI                            | 2 (5.7)               | 4 (11.4)              | 2 (6.3)                | 0.933‡     | 0.727 |
| Diuretic                       | 2 (5.7)               | 4 (11.4)              | 3 (9.4)                | 0.805‡     | 0.759 |
| CYP2C19 genotype               |                       |                       |                        | 2.392‡     | 0.664 |
| Extensive metabolizers         | 15 (42.9)             | 12 (34.3)             | 13 (41.9)              |            |       |
| Intermediate metabolizers      | 12 (34.3)             | 18 (51.4)             | 13 (41.9)              |            |       |
| Poor metabolizers              | 8 (22.8)              | 5 (14.3)              | 5 (16.2)               |            |       |
| Lesion types of target vessel  |                       |                       |                        |            |       |
| Left main disease              | 0                     | 2 (5.7)               | 2 (6.3)                | 2.265†     | 0.460 |
| Long lesions                   | 35 (100.0)            | 34 (97.1)             | 30 (93.8)              | 2.068‡     | 0.307 |
| Tortuous lesions               | 0                     | 1 (2.9)               | 2 (6.3)                | 2.068‡     | 0.307 |
| Small vascular lesions         | 1 (2.9)               | 3 (8.6)               | 3 (9.4)                | 1.450†     | 0.621 |
| Heavy calcification            | 2 (5.7)               | 3 (8.6)               | 4 (12.5)               | 1.002‡     | 0.624 |
| In-stent restenosis            | 2 (5.7)               | 4 (11.4)              | 3 (9.4)                | 0.805‡     | 0.759 |
| Platelet counts (x 10⁹/L)      | 222.31 ± 65.40        | 232.29 ± 50.78        | 209.00 ± 45.19         | 1.519†     | 0.224 |
| CrCl (mL/min)                  | 107.04 ± 29.22        | 104.55 ± 27.52        | 105.17 ± 33.83         | 0.064*     | 0.938 |
| Hematocrit (%)                 | 43.38 ± 4.39          | 42.47 ± 3.99          | 42.27 ± 3.74           | 0.728*     | 0.486 |

Data were shown as n (%) or mean ± SD. *F test, †χ² test, ‡T-90 mg-12 h: Maintenance dose of 90 mg of ticagrelor at 12 h after the last clopidogrel treatment; T-90 mg-24 h: Maintenance dose of 90 mg of ticagrelor at 24 h after the last clopidogrel treatment; T-180 mg-24 h: Loading dose of 180 mg of ticagrelor at 24 h after the last clopidogrel treatment; BMI: Body mass index; MI: Myocardial infarction; PAD: Peripheral arterial disease; PCI: Percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction; UA: Unstable angina; NSTEMI: Non-ST-segment elevation myocardial infarction; CCB: Calcium-channel inhibitor; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blocker; PPI: Proton-pump inhibitor; CrCl: Creatinine clearance; −: Not applicable; SD: Standard deviation.

the time interval (the time interval from the last dose of clopidogrel administration to the shift to ticagrelor) and the dosage of ticagrelor were included in a stepwise linear regression model to assess the association between the MPA at 8 h and the time interval or dosage. The results showed that the MPA at 8 h was a negative correlation to the time interval (Beta = -0.360, P < 0.001). It was also noticeable that compared with the T-90 mg-24 h group, the T-90 mg-12 h group exhibited a numerical increase in the proportion of patients with HPR at either 2 or 8 h after switching the treatment strategy (8.6% vs. 5.7%, P(2h) = 0.367; 5.7% vs. 0, P(8 h) = 0.327) [Table 2].

Safety and tolerability

First, one case of fundus hemorrhage occurred in the T-90 mg-12 h group, and this patient withdrew from the study. In addition, none of the patients suffered life-threatening adverse events in our study during the whole follow-up period. At 30 days after discharge, the incidence of BARC one bleeding events was 34.3% in the T-90 mg-12h group, 42.9% in the T-90 mg-24 h group, and 31.3% in the T-180 mg-24 h group (P = 0.587). The results of bleeding episodes classified by BARC, TIMI, or PLATO criteria were shown in Table 3, with similar conclusions were achieved. Dyspnea occurred in the T-90 mg-12 h group for 10 (28.6%) events, in the T-90 mg-24 h group for 10 (25.0%) events at 30 days after discharge (P = 0.932). The majority of dyspnea events were mild and only one patient with dyspnea in the T-180 mg-24 h group dropped out prematurely because of intolerability. The median duration in our hospital for PCI-treated patients is 6 (5–7) days. The results during hospitalization were the same as those at
30 days after discharge [Table 3]. No deaths were reported during the whole follow-up period.

Discussion

Among Chinese patients with ACS with complicated CAD managed by PCI, considering all outcomes of the platelet function assays and adverse events, switching to a loading dose of ticagrelor or a maintenance dose of ticagrelor at 24 h after the last dose of clopidogrel is the optimal transformation strategy. Switching from clopidogrel to a bolus of 180 mg of ticagrelor in the early phase is consistent with the updated ESC dual anti-platelet guidelines, whereas the switching strategy without a reloading dose is similar to SHIFT-OVER study.[1,23,26] Yet, they lack the best switching time as well as Chinese patients with complicated CAD. However, it is important to concentrate on the best switching time, as a result of, during non-acute phase (≥24 h from ACS or PCI), switching to a loading dose of ticagrelor pre-maturely, high bleeding risk might be observed in Chinese patients, who are inclined to have a higher bleeding risk than non-Asians.[27,28] Moreover, Chinese patients with a high mortality of CAD or Asians with a different response to ticagrelor were not included in the ESC dual anti-platelet guidelines and other trials.[29-31] A well-known fact is that, treatment with ticagrelor is preferred in patients with complicated CAD, as ticagrelor has been shown to be superior to clopidogrel in reducing the recurrence of ischemic events.[8-10] However, in the real world, treatment with clopidogrel is more common before coronary angiography because of costs and side effects; thus, various conversion regimens from clopidogrel to ticagrelor have been conducted in clinical practice and are still under debate.[23,26] In the PLATO trial, nearly half of patients initiated clopidogrel treatment and then switched to a 180 mg loading dose of ticagrelor followed by 90 mg of ticagrelor twice daily regardless of the timing of their last dose of clopidogrel, and all patients received benefits from ticagrelor therapy.[8] The strategy of switching from clopidogrel to ticagrelor was performed in patients with stable CAD who were either responders or non-responders according to HPR status in the Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies (RESPOND) study. The RESPOND study, in which various pharmacodynamic assays were performed, indicated that all patients who switched their treatment to ticagrelor showed a significant reduction in platelet reactivity.[12,13] The above two large studies were not tailored to determine the optimal switching strategy, whereas our study analyzed the dose and time point of switching from clopidogrel to ticagrelor in Chinese patients with ACS with complicated CAD by comparing the pharmacodynamic assessments and adverse events among three groups with different dosages and timing. For pharmacodynamic assessments, routine platelet function testing was not recommended by the guidelines as a result of low cost-effectiveness and poor accuracy which attributed to individual difference, operational error, and laboratory environment. However, certain predictability for ischemic events of platelet function testing and the clinical utility of platelet function testing for guiding anti-platelet therapy has been proved by some previous trials. So, it is beneficial to evaluate the effect of anti-platelet drugs via using platelet function testing, especially for acute phase. Additionally, the LTA with strong clinical practicability and long experience for good predictability

![Figure 2: Pharmacodynamic comparisons among groups. Comparisons of mean maximal platelet aggregation measured by light transmittance aggregometry among groups after switching from clopidogrel to ticagrelor therapy. Data were shown as the mean ± SE.](image)

Baseline values were measured while on clopidogrel maintenance therapy. Before discharge values were measured at 2 h after the last dose of ticagrelor during hospital. The \( P \) value denoted the T-90 mg-12 h group comparing with the T-180 mg-24 h group at 2 h after switching strategies; the \( P \) value denoted the T-90 mg-12 h group comparing with the T-90 mg-24 h group at 8 h after switching strategies; the \( P \) value denoted the T-90 mg-12 h group comparing with the T-180 mg-24 h group at 8 h after switching strategies. MPA: Maximal platelet aggregation; SE: Standard error; T-90 mg-12 h: Maintenance dose of 90 mg of ticagrelor at 12 h after the last clopidogrel treatment; T-90 mg-24 h: Maintenance dose of 90 mg of ticagrelor at 24 h after the last clopidogrel treatment; T-180 mg-24 h: Loading dose of 180 mg of ticagrelor at 24 h after the last clopidogrel treatment.

### Table 2: High on-treatment platelet reactivity events of the Chinese patients with acute coronary syndrome and complicated coronary artery (MPA >59%).

| Variables | T-90 mg-12 h (n = 35) | T-90 mg-24 h (n = 35) | T-180 mg-24 h (n = 32) | \( \chi^2 \) | \( P \) |
|-----------|-----------------------|-----------------------|------------------------|---------------|---------------|
| Baseline  | 25 (71.4)             | 23 (65.7)             | 22 (68.8)              | 0.266         | 0.876         |
| 2 h       | 3 (8.6)               | 2 (5.7)               | 0                      | 2.630         | 0.367         |
| 8 h       | 2 (5.7)               | 0                     | 0                      | 2.593         | 0.327         |
| Before discharge | 0 | 0 | – | 1.000 |

Data were shown as \( n \) (%). Baseline values were measured while on clopidogrel maintenance therapy. Before discharge values were measured at 2 h after the last dose of ticagrelor during hospital. MPA: Maximal platelet aggregation; T-90 mg-12 h: Maintenance dose of 90 mg of ticagrelor at 12 h after the last clopidogrel treatment; T-90 mg-24 h: Maintenance dose of 90 mg of ticagrelor at 24 h after the last clopidogrel treatment; T-180 mg-24 h: Loading dose of 180 mg of ticagrelor at 24 h after the last clopidogrel treatment; –: Not applicable.
During hospitalization, inhibition of platelet aggregation by clopidogrel, which the occupied P2Y12 receptors might be incompletely cleared at 12 h after clopidogrel. However, this finding was contrary to the Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention (CAPITAL RELOAD) study reported in 2014, which demonstrated a positive pharmacodynamic interaction between clopidogrel and ticagrelor regardless of the interval time. Importantly, according to a recent study, we inferred that the occupied P2Y12 receptors might be incompletely cleared at 12 h compared to 24 h after the application of ticagrelor. This phenomenon corresponded to the inhibition of platelet aggregation by clopidogrel, which could last for a longer time. Thus, we hypothesized that a higher level of occupied P2Y12 receptors, which was inversely proportional to time, corresponded with a stronger influence on the subsequent binding drugs. We tried to acquire some clues for further exploring the drug interactions based on the recently updated viewpoints. The traditional non-competitive mode of inhibiting the ADP binding site with ticagrelor was challenged by a competitive mode, in which the Cys194 residue of the P2Y12 receptor protein contributed to the recognition of ticagrelor, whereas clopidogrel interacted with the Cys97 residue of the receptor protein, but structurally, the two residues were not the unique binding sites, and whether the distance between the two residues was far enough to not severely affect the binding of ticagrelor with P2Y12 when clopidogrel was bound still requires further clarification. All the above new viewpoints might be coincided with the mild negative impact on ticagrelor pharmacodynamics at 12 h after the last dose of clopidogrel. As we all know, the early phase after PCI or ACS could be a potential vulnerable period for ischemic complications especially in patients with complicated CAD, who may be more prone to stent thrombosis. Overall, the assumption of the interaction of receptor binding sites and the updated mechanisms might make it possible for us to avoid the transformation that occurs at 12 h after medication, which is based on the possible negative pharmacodynamics between the overlap for clopidogrel and ticagrelor detected in this study at 12 h after clopidogrel treatment. This finding further supports that the optimal transformation time point is 24 h after the

was employed in this study to balance the debate of the low cost-effectiveness and accuracy in Chinese patients. Finally, the results revealed that the T-180 mg-24 h group and the T-90 mg-24 h group exhibited the greatest efficacy in the pharmacodynamic assessments. The most common reasons for discontinuing ticagrelor therapy are bleeding and dyspnea, and treatment interruption is associated with poor prognosis. Moreover, these adverse events are typically observed when patients are treated with a high-dose of ticagrelor. However, treatment of patients with a 180 mg bolus of ticagrelor did not increase the proportion of adverse events compared with managed by the standard dose in the present study.

Another noticeable discovery is that the difference between the T-90 mg-12 h group and the T-90 mg-24 h group in pharmacodynamic assessments suggests the presence of a negative pharmacodynamic interaction between the overlap for clopidogrel and ticagrelor at 12 h after the last dose of clopidogrel. However, this finding was contrary to the Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention (CAPITAL RELOAD) study reported in 2014, which demonstrated a positive pharmacodynamic interaction between clopidogrel and ticagrelor regardless of the interval time. Importantly, according to a recent study, we inferred that the occupied P2Y12 receptors might be incompletely cleared at 12 h compared to 24 h after the application of ticagrelor. This phenomenon corresponded to the inhibition of platelet aggregation by clopidogrel, which could last for a longer time. Thus, we hypothesized that a higher level of occupied P2Y12 receptors, which was inversely proportional to time, corresponded with a stronger influence on the subsequent binding drugs. We tried to acquire some clues for further exploring the drug interactions based on the recently updated viewpoints. The traditional non-competitive mode of inhibiting the ADP binding site with ticagrelor was challenged by a competitive mode, in which the Cys194 residue of the P2Y12 receptor protein contributed to the recognition of ticagrelor, whereas clopidogrel interacted with the Cys97 residue of the receptor protein, but structurally, the two residues were not the unique binding sites, and whether the distance between the two residues was far enough to not severely affect the binding of ticagrelor with P2Y12 when clopidogrel was bound still requires further clarification. All the above new viewpoints might be coincided with the mild negative impact on ticagrelor pharmacodynamics at 12 h after the last dose of clopidogrel. As we all know, the early phase after PCI or ACS could be a potential vulnerable period for ischemic complications especially in patients with complicated CAD, who may be more prone to stent thrombosis. Overall, the assumption of the interaction of receptor binding sites and the updated mechanisms might make it possible for us to avoid the transformation that occurs at 12 h after medication, which is based on the possible negative pharmacodynamics between the overlap for clopidogrel and ticagrelor detected in this study at 12 h after clopidogrel treatment. This finding further supports that the optimal transformation time point is 24 h after the

was employed in this study to balance the debate of the low cost-effectiveness and accuracy in Chinese patients. Finally, the results revealed that the T-180 mg-24 h group and the T-90 mg-24 h group exhibited the greatest efficacy in the pharmacodynamic assessments. The most common reasons for discontinuing ticagrelor therapy are bleeding and dyspnea, and treatment interruption is associated with poor prognosis. Moreover, these adverse events are typically observed when patients are treated with a high-dose of ticagrelor. However, treatment of patients with a 180 mg bolus of ticagrelor did not increase the proportion of adverse events compared with managed by the standard dose in the present study.

Another noticeable discovery is that the difference between the T-90 mg-12 h group and the T-90 mg-24 h group in pharmacodynamic assessments suggests the presence of a negative pharmacodynamic interaction between the overlap for clopidogrel and ticagrelor at 12 h after the last dose of clopidogrel. However, this finding was contrary to the Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention (CAPITAL RELOAD) study reported in 2014, which demonstrated a positive pharmacodynamic interaction between clopidogrel and ticagrelor regardless of the interval time. Importantly, according to a recent study, we inferred that the occupied P2Y12 receptors might be incompletely cleared at 12 h compared to 24 h after the application of ticagrelor. This phenomenon corresponded to the inhibition of platelet aggregation by clopidogrel, which could last for a longer time. Thus, we hypothesized that a higher level of occupied P2Y12 receptors, which was inversely proportional to time, corresponded with a stronger influence on the subsequent binding drugs. We tried to acquire some clues for further exploring the drug interactions based on the recently updated viewpoints. The traditional non-competitive mode of inhibiting the ADP binding site with ticagrelor was challenged by a competitive mode, in which the Cys194 residue of the P2Y12 receptor protein contributed to the recognition of ticagrelor, whereas clopidogrel interacted with the Cys97 residue of the receptor protein, but structurally, the two residues were not the unique binding sites, and whether the distance between the two residues was far enough to not severely affect the binding of ticagrelor with P2Y12 when clopidogrel was bound still requires further clarification. All the above new viewpoints might be coincided with the mild negative impact on ticagrelor pharmacodynamics at 12 h after the last dose of clopidogrel. As we all know, the early phase after PCI or ACS could be a potential vulnerable period for ischemic complications especially in patients with complicated CAD, who may be more prone to stent thrombosis. Overall, the assumption of the interaction of receptor binding sites and the updated mechanisms might make it possible for us to avoid the transformation that occurs at 12 h after medication, which is based on the possible negative pharmacodynamics between the overlap for clopidogrel and ticagrelor detected in this study at 12 h after clopidogrel treatment. This finding further supports that the optimal transformation time point is 24 h after the
last clopidogrel treatment, which concurred with the pharmacodynamic assessments above. Additional larger studies are warranted to assess the pharmacokinetics to verify this conclusion.

The present study was certainly not without limitations. First, our study was an open-label study with inherent biases. Nevertheless, all the adverse events that occurred during hospitalization were adjudicated by clinicians who were unaware of treatment allocations to minimize the potential biases. Second, although a larger sample size and a various measure of platelet functions were needed in our study, such studies are difficult to implement because we are a developing country and the platelet function testing by verifitynow and vasodilator stimulated phosphoprotein costs more than 10% of a per capita disposable income every year in Liaoning, China. Nevertheless, the results of the pharmacodynamics and adverse reactions might still provide a reference for switching from clopidogrel to ticagrelor treatment. Third, 180 mg of ticagrelor at 12 h after clopidogrel treatment was not evaluated in our study because Asians are believed to have a higher bleeding risk during anti-thrombotic therapy. Whether there are benefits to this switching therapies remains unknown. Finally, the potential interrelationship observed between the overlap for clopidogrel and ticagrelor in our study did not lead to a definitive conclusion due to the absence of pharmacokinetic measurements of ticagrelor, its major metabolite and the active metabolite of clopidogrel. Therefore, the potential mechanism of the interaction between the overlap for these drugs warrants further study.

In conclusion, the present study showed that ACS Chinese patients with complicated CAD managed by PCI can indeed benefit from switching from clopidogrel to ticagrelor for platelet inhibition. Our data suggests based on the pharmacodynamic assessments and adverse events that switching to ticagrelor with a bolus of 180 or 90 mg at 24 h after the last dose of clopidogrel is the optimal therapy in Chinese patients with ACS with complicated CAD managed by PCI. Furthermore, this study indicates that there seems to be a negative interaction between the overlap for clopidogrel and ticagrelor at 12 h after the last dose of clopidogrel. Additional larger studies are warranted to further verify the conclusions of our trial.

Acknowledgement

The authors thank for the help from Dr. Xiao-Xiang Tian in preparing this manuscript.

Funding

This work was supported by a grant from the National Key Research and Development Project (No. 2016YFC1301300).

Conflicts of interest

None.

References

1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jezperson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213–260. doi: 10.1093/eurheartj/ehx419.

2. Levine GN, Bates ER, Birnl JA, Brindis RG, Fihn SD, Flesher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2016;152:1243–1275. doi: 10.1016/j.jtcs.2016.07.044.

3. Magro M, Nauta S, Simsek C, Onuma Y, Garg S, van der Heide E, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAX score study. Am Heart J 2011;161:771–781. doi: 10.1016/j.ahj.2011.01.004.

4. Savonitto S, Morici N, Franco N, Misuraca L, Lenatti L, Ferri LA, et al. Age at menopause, extent of coronary artery disease and outcome among postmenopausal women with acute coronary syndromes. Int J Cardiol 2018;259:8–13. doi: 10.1016/j.ijcard.2018.02.063.

5. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, Mehran R, et al. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2011;57:2389–2397. doi: 10.1016/j.jacc.2011.02.032.

6. Danielak D, Karaźniewicz-Lada M, Główka F. Ticagrelor in modern cardiology—an up-to-date review of most important aspects of ticagrelor pharmacotherapy. Expert Opin Pharmacother 2018;19:103–112. doi: 10.1080/14656566.2017.1426364.

7. Gurbel PA, Bilen KP, Butler K, Tantry US, Geshell T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577–2585. doi: 10.1161/CIRCULATIONAHA.109.912550.

8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057. doi: 10.1056/NEJMoa0904327.

9. Kotsis A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: insights from the PLATElet inhibition and patient outcomes (PLATO) trial. Am Heart J 2014;168:5–8. doi: 10.1016/j.ahj.2014.04.001.

10. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:587–165. doi: 10.1093/eurheartj/ehy394.

11. Becker RC, Bassand JP, Budaj A, Woydyla DM, James SK, Cornel JH, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient outcomes (PLATO) trial. Eur Heart J 2011;32:2933–2944. doi: 10.1093/eurheartj/ehr422.

12. Storey RF, Becker RC, Harrington RA, Husted S, James SK, Cools F, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32:2945–2953. doi: 10.1093/eurheartj/ehr231.

13. Alexopoulos D, Xanthopoulos I, Deftereos S, Sifaitis G, Kanakakis I, Hannos M, et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J 2014;167:68–76.e2. doi: 10.1016/j.ahj.2013.10.010.

14. General Assembly of the World Medical Association. . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 2014;81:14–18.

15. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219–227.

16. Cattralose M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158–167. doi: 10.1055/s-0029-1220324.
17. Franchi F, Rollini F, Rivas Rios J, Rivas A, Agarwal M, Kureti M, et al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation 2018;137:2450–2462. doi: 10.1161/CIRCULATIONAHA.118.033983.

18. Garbel PA, Gesheff MG, Frantsuz CF, Bliden KP, Tang US. Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy? Platelets 2015;26:608–609. doi: 10.1080/09537104.2014.920497.

19. Tang US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al. Concordance and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273. doi: 10.1016/j.jacc.2013.07.101.

20. Garbel PA, Antonino MJ, Bliden KP, Dichiara J, Suarez TA, Singla A, et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008;19:595–604. doi: 10.1080/09537100802351065.

21. Chesebro JH, Knatterud G, Roberts R, Rorer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase II: a comparison between intravenous tissue plasminogen activator, and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142–154. doi: 10.1161/01.cir.76.1.142.

22. Hicks KA, Stockbridge NL, Targum SL, Temple RJ. Bleeding and patient outcomes (PLATO) trial. Am Heart J 2015;169:899–919. doi: 10.1016/j.ahj.2015.03.015.

23. Liu J, Li X, Wang Q, Su S, Wang Y, Masoudi FA, et al. Retraction and republication—SI-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2015;385:402. doi: 10.1016/S0140-6736(14)62216-9.

24. Gurbel PA, Giampà S, Braun OÖ, et al. Competitive mode and site of interaction of ticagrelor with the antiplatelet drug. Nature 2014;509:115–118. doi: 10.1038/nature13189.

25. Caiazzo G, De Rosa S, Torella D, Spaccarotella C, Mongiardo A, et al. Pharmacokinetic, pharmacodynamic, and safety data of low-dose ticagrelor versus standard dose in East Asians: a systematic review. Ther Clin Risk Manag 2018;14:83–93. doi: 10.2147/TCRM.2017.12276.

26. Hhiba B, Maze R, Pourjadbab A, Simard T, Ramirez FD, Moudgil R, et al. A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study. PLoS One 2014;9:e92078. doi: 10.1371/journal.pone.0092078.

27. Cattaneo M. Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks. Eur J Heart 2016;57:2731–2733. doi: 10.1093/euheartj/eow103.

28. VAN Geenen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009;7:1556–1565. doi: 10.1111/j.1538-7836.2009.03527.x.

29. Hoffmann K, Lutz DA, Straßburger J, Baqi Y, Müller CE, von Kugelgen I. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y12 receptor. J Thromb Haemost 2014;12:1898–1905. doi: 10.1111/jth.12719.

30. Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, et al. Structure of the human P2Y12 receptor in complex with an anthrithrombic drug. Nature 2014;509:115–118. doi: 10.1038/nature13083.

31. Pourjadbab A, Hhiba B, Chong AY, Lee May MR, Labinaiz M, Simard T, et al. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS study. Thromb Haemost 2017;117:303–310. doi: 10.1160/TH16-04-0340.

32. Garbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005;46:1820–1826. doi: 10.1016/j.jacc.2005.07.041.

33. Guan H, Wang Y. School of Economics, Shenyang University. Correlation degree and difference between consumption and actual income of urban and rural residents in liaoning: based on analysis of cointegration and ECM model. J Shenyang Univ 2017;19:153–157. doi: 10.16103/j.cnki.21-1382/c.2017.02.006.

**How to cite this article:** Yao Y, Wang P, Wang XZ, Zhao X, Zhao W, Zhou TN, Zhang L. Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study. Chin Med J 2019;132:2292–2299. doi: 10.1097/CM9.0000000000004444.